Vertex Pharmaceuticals rises on strong cystic fibrosis sales and promising kidney drug trials, UBS hikes price target.

Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential. The company’s kidney drug inaxaplin showed promising Phase 2b trial results, significantly reducing kidney damage in patients with a genetic kidney disease. This progress signals successful diversification beyond cystic fibrosis, supporting the higher valuation and future growth prospects.

As of Sep 28, 2026 22:33 WIB, Vertex Pharmaceuticals (VRTX) trades at USD 528.29 on Pluang, close to its 52-week high of USD 557.96 and well above its 52-week low of USD 385.74. The stock shows a modest 1-day gain of 0.40%, reflecting steady investor interest amid its recent positive developments. With a market cap of $133.37 billion, VRTX remains a significant player in the health sector, maintaining a typical hold time of 119 days on Pluang.